Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 594–595 (2006)Cite this article

boxed-textMcKenney JM et al. (2006) Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 47: 1584–1587

Statins should be first-line agents in the management of dyslipidemia, but for patients who have difficulty tolerating these drugs, a combination of ezetimibe and fenofibrate is now an approved alternative

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kosoglou T et al. (2005) Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44: 467–494

    Article  CAS  Google Scholar 

  2. Merck/Schering-Plough Pharmaceuticals (2002) Zetia® (ezetimibe) package insert. MSP Marketing Services, West Point, PA

  3. Farnier M et al. (2005) Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 26: 897–905

    Article  CAS  Google Scholar 

  4. Davidson MH (2006) Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 5: 145–156

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine and Director of the Preventive Cardiology Center at Rush University Medical Center and Executive Medical Director of Radiant Research, Chicago, IL, USA

    Michael H Davidson

Authors
  1. Michael H Davidson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael H Davidson.

Ethics declarations

Competing interests

Dr Davidson has received grant/research support from Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Kos Pharmaceuticals, Merck & Co., Merck/Schering-Plough, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, Reliant Pharmaceuticals, Roche Pharmaceuticals, Sankyo Pharmaceuticals and Takeda Pharmaceuticals. He has acted as a consultant for Abbott Laboratories, AstraZeneca Pharmaceuticals, Kos Pharmaceuticals, Merck & Co., Merck/Schering-Plough, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, Reliant Pharmaceuticals, Roche Pharmaceuticals, Sankyo Pharmaceuticals, Sumitomo Pharmaceuticals and Takeda Pharmaceuticals. He has also served the speaker's bureau for Abbott Laboratories, AstraZeneca Pharmaceuticals, Kos Pharmaceuticals, Merck & Co., Merck/Schering-Plough, Pfizer Pharmaceuticals, Reliant Pharmaceuticals, Sankyo Pharmaceuticals and Takeda Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davidson, M. Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?. Nat Rev Cardiol 3, 594–595 (2006). https://doi.org/10.1038/ncpcardio0689

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0689

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing